Related Experiment Video
Updated: Jan 13, 2026
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
18.8K
Artemis (DCLRE1C) Acts as a Target to Enhance Radiotherapy Response in Triple-Negative Breast Cancer
Vasudeva Bhat1,2,3, Kelsie L Thu4,5, Anayra de Fatima Goncalves Santiago1
1Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 3K7, Canada.
Cancers
|October 29, 2025
Summary
Targeting Artemis, a novel radioresistance gene, can enhance radiotherapy response in triple-negative breast cancer (TNBC). Inhibiting Artemis promotes radiosensitization and improves treatment outcomes for TNBC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Triple-negative breast cancer (TNBC) lacks biomarkers and effective strategies against radioresistance, leading to poor outcomes.
- Identifying novel radioresistance genes is crucial for improving radiotherapy response in TNBC.
Purpose of the Study:
- To identify and characterize novel radioresistance genes in TNBC.
- To evaluate Artemis as a potential therapeutic target to enhance radiotherapy efficacy in TNBC.
Main Methods:
- Genome-wide CRISPR screen in TNBC cells to identify radioresistance genes.
- In vitro and in vivo assays (clonogenic, xenograft) to assess Artemis function and radiosensitization.
- RNA-sequencing and senescence assays to elucidate underlying mechanisms.
Main Results:
- Artemis was identified as a key radioresistance gene in TNBC.
- Artemis knockout sensitized TNBC cells to radiation, reducing proliferation and enhancing RT effects in vitro and in vivo.
- Artemis depletion induced cellular senescence, mediating its radiosensitizing effects.
Conclusions:
- Artemis plays a critical role in TNBC proliferation and radioresistance.
- Artemis is a potential biomarker for radiation sensitivity and a therapeutic target to improve RT efficacy in TNBC.
Related Concept Videos
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K